Literature DB >> 21761347

Estrogen-induced aurora kinase-A (AURKA) gene expression is activated by GATA-3 in estrogen receptor-positive breast cancer cells.

Shoulei Jiang1, Hiroshi Katayama, Jin Wang, Sara Antonia Li, Yan Hong, Laszlo Radvanyi, Jonathan J Li, Subrata Sen.   

Abstract

Aurora-A is a proto-oncogenic mitotic kinase that is frequently overexpressed in human epithelial malignancies including in breast and ovarian cancers. The mechanism of transcriptional upregulation of Aurora-A in human breast cancer is not yet elucidated. We report herein that Aurora-A transcription is positively regulated by GATA-3 in response to estrogen in estrogen receptor α (ERα)-positive cells. Transient expression of aurora-A promoter deletion mutants in luciferase constructs identified a GATA binding sequence motif as a functional regulatory element in ERα-positive breast cancer cells. Electrophoretic mobility shift assay identified the binding of regulatory proteins to the GATA element. Anti-GATA-3 antibody generated a supershifted complex. Recruitment of GATA-3 to the aurora-A promoter was verified by chromatin immunoprecipitation analysis with GATA-3 antibody. Ectopic expression of GATA-3 resulted in elevated expression of Aurora-A in both ERα-positive and negative cells while siRNA-mediated silencing led to downregulation of endogenous Aurora-A in ERα-positive cells. Estrogen treatment of ERα-positive cells induced increased Aurora-A expression with enhanced recruitment of GATA-3 to the aurora-A promoter. Finally, in the ACI rat model of estrogen-induced breast cancer, known to be associated with elevated Aurora-A expression, we observed increased expression of GATA-3 in preinvasive and invasive mammary epithelial cells exposed to prolonged estrogen treatment and in developing breast tumors. These results demonstrate a direct positive role of estrogen in regulating Aurora-A expression through activation of the ERα-GATA-3 signaling cascade and suggest that this pathway may be critical in the origin of estrogen-stimulated sporadic breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21761347      PMCID: PMC4501777          DOI: 10.1007/s12672-010-0006-x

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  38 in total

Review 1.  Estrogen and the risk of breast cancer.

Authors:  M Clemons; P Goss
Journal:  N Engl J Med       Date:  2001-01-25       Impact factor: 91.245

2.  Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.

Authors:  Tatiana M Gritsko; Domenico Coppola; June E Paciga; Lin Yang; Mei Sun; Sue A Shelley; James V Fiorica; Santo V Nicosia; Jin Q Cheng
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

3.  Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1.

Authors:  Masatsugu Tanaka; Atsuhisa Ueda; Heiwa Kanamori; Haruko Ideguchi; Jun Yang; Shigetaka Kitajima; Yoshiaki Ishigatsubo
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

4.  Prevention of solely estrogen-induced mammary tumors in female aci rats by tamoxifen: evidence for estrogen receptor mediation.

Authors:  S A Li; S J Weroha; O Tawfik; J J Li
Journal:  J Endocrinol       Date:  2002-11       Impact factor: 4.286

5.  Gene expression profiling of primary breast carcinomas using arrays of candidate genes.

Authors:  F Bertucci; R Houlgatte; A Benziane; S Granjeaud; J Adélaïde; R Tagett; B Loriod; J Jacquemier; P Viens; B Jordan; D Birnbaum; C Nguyen
Journal:  Hum Mol Genet       Date:  2000-12-12       Impact factor: 6.150

6.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

7.  Centrosome amplification drives chromosomal instability in breast tumor development.

Authors:  Wilma L Lingle; Susan L Barrett; Vivian C Negron; Antonino B D'Assoro; Kelly Boeneman; Wanguo Liu; Clark M Whitehead; Carol Reynolds; Jeffrey L Salisbury
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-05       Impact factor: 11.205

8.  Centrosome amplification and overexpression of aurora A are early events in rat mammary carcinogenesis.

Authors:  Thea M Goepfert; Yetunde E Adigun; Ling Zhong; Jason Gay; Daniel Medina; William R Brinkley
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

9.  AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol.

Authors:  Shubha Anand; Sue Penrhyn-Lowe; Ashok R Venkitaraman
Journal:  Cancer Cell       Date:  2003-01       Impact factor: 31.743

10.  The NFY transcription factor inhibits von Willebrand factor promoter activation in non-endothelial cells through recruitment of histone deacetylases.

Authors:  Yiwen Peng; Nadia Jahroudi
Journal:  J Biol Chem       Date:  2003-01-02       Impact factor: 5.157

View more
  17 in total

1.  Systematic identification of the HSP90 candidate regulated proteome.

Authors:  Zhixiang Wu; Amin Moghaddas Gholami; Bernhard Kuster
Journal:  Mol Cell Proteomics       Date:  2012-02-14       Impact factor: 5.911

2.  Transcriptomic analysis to elucidate the molecular mechanisms that underlie feed efficiency in meat-type chickens.

Authors:  Jeeyoung Lee; Arthur B Karnuah; Romdhane Rekaya; Nicholas B Anthony; Samuel E Aggrey
Journal:  Mol Genet Genomics       Date:  2015-03-18       Impact factor: 3.291

Review 3.  Induced mammary cancer in rat models: pathogenesis, genetics, and relevance to female breast cancer.

Authors:  James L Miller; Arianna P Bartlett; Rebecca M Harman; Prabin Dhangada Majhi; D Joseph Jerry; Gerlinde R Van de Walle
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-07-29       Impact factor: 2.698

Review 4.  Rat models of 17β-estradiol-induced mammary cancer reveal novel insights into breast cancer etiology and prevention.

Authors:  James D Shull; Kirsten L Dennison; Aaron C Chack; Amy Trentham-Dietz
Journal:  Physiol Genomics       Date:  2018-01-26       Impact factor: 3.107

5.  Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.

Authors:  George Notas; Marilena Kampa; Vassiliki Pelekanou; Maria Troullinaki; Yves Jacquot; Guy Leclercq; Elias Castanas
Journal:  Mol Oncol       Date:  2013-02-20       Impact factor: 6.603

Review 6.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

7.  Prognosis value of mitotic kinase Aurora-A for primary duodenal adenocarcinoma.

Authors:  Jie Chen; Qu Lin; Jing-Yun Wen; Xing Li; Xiao-Kun Ma; Xin-Juan Fan; Qin-Hua Cao; Min Dong; Li Wei; Zhan-Hong Chen; Xiao-Yun Li; Tian-Tian Wang; Quentin Liu; Xiang-Bo Wan; Yan-Fang Xing; Xiang-Yuan Wu
Journal:  Tumour Biol       Date:  2014-06-20

8.  Estrogenic regulation of S6K1 expression creates a positive regulatory loop in control of breast cancer cell proliferation.

Authors:  D M Maruani; T N Spiegel; E N Harris; A S Shachter; H A Unger; S Herrero-González; M K Holz
Journal:  Oncogene       Date:  2012-01-30       Impact factor: 9.867

9.  Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients.

Authors:  Steen Knudsen; Thomas Jensen; Anker Hansen; Wiktor Mazin; Justin Lindemann; Irene Kuter; Naomi Laing; Elizabeth Anderson
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.240

10.  Infrequent loss of luminal differentiation in ductal breast cancer metastasis.

Authors:  Julia Calvo; Lourdes Sánchez-Cid; Montserrat Muñoz; Juan José Lozano; Timothy M Thomson; Pedro L Fernández
Journal:  PLoS One       Date:  2013-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.